FDA Approves Neffy: First Needle-Free Epinephrine Nasal Spray for Allergic Reactions

Neffy offers an alternative to EpiPen, aiming to reduce treatment hesitation among those with severe allergies.

Neffy is approved for use in adults and children weighing at least 66 pounds.
The nasal spray provides a needle-free option for treating life-threatening anaphylaxis.
Studies show Neffy delivers comparable epinephrine levels to injectable products.
Common side effects include nasal discomfort, headache, and nausea.
ARS Pharmaceuticals plans to make Neffy available in the U.S. within eight weeks.